康辰药业
(603590)
| 流通市值：44.95亿 | | | 总市值：45.66亿 |
| 流通股本：1.58亿 | | | 总股本：1.60亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 720,036,091.76 | 450,835,547.87 | 165,105,876.86 | 866,725,922.18 |
| 营业收入 | 720,036,091.76 | 450,835,547.87 | 165,105,876.86 | 866,725,922.18 |
| 二、营业总成本 | 548,847,055.47 | 347,351,653.19 | 134,552,802.26 | 727,448,839.1 |
| 营业成本 | 73,224,258.27 | 47,485,094.04 | 17,589,610.28 | 126,157,429.29 |
| 税金及附加 | 4,635,447.32 | 3,031,324.32 | 1,402,059.51 | 6,499,162.73 |
| 销售费用 | 344,485,348.01 | 219,534,621.33 | 75,548,574.1 | 423,153,323.43 |
| 管理费用 | 70,316,034.87 | 46,301,448.29 | 20,637,248.45 | 102,724,408.41 |
| 研发费用 | 67,219,009.8 | 40,286,678.85 | 21,243,679.4 | 86,775,881.64 |
| 财务费用 | -11,033,042.8 | -9,287,513.64 | -1,868,369.48 | -17,861,366.4 |
| 其中:利息费用 | 1,229,074.15 | 615,479.06 | 297,322.6 | 864,064.33 |
| 其中:利息收入 | 10,015,249.25 | 6,873,250 | 3,244,584.95 | 18,515,415.48 |
| 加:公允价值变动收益 | -1,640,679.72 | -1,737,432.38 | 522,452.05 | -6,569,582.55 |
| 加:投资收益 | 10,783,293.54 | 10,163,514.81 | 1,380,755.26 | -1,077,121.78 |
| 资产减值损失(新) | - | - | - | -4,555,015.08 |
| 信用减值损失(新) | -2,088,501 | -80,165.55 | 1,388,593.79 | -2,181,782.9 |
| 其他收益 | 10,282,442.05 | 8,808,459.99 | 1,988,080.37 | 15,810,331.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 188,525,591.16 | 120,638,271.55 | 35,832,956.07 | 140,703,912.75 |
| 加:营业外收入 | 257,558.67 | 57,380.89 | 50,185.37 | 506,619.63 |
| 减:营业外支出 | 1,008,680.02 | 805,778.16 | 802,239.84 | 893,557.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 187,774,469.81 | 119,889,874.28 | 35,080,901.6 | 140,316,975.22 |
| 减:所得税费用 | 24,935,546.99 | 16,516,012.79 | 5,216,505.74 | 16,422,064.11 |
| 六、净利润 | 162,838,922.82 | 103,373,861.49 | 29,864,395.86 | 123,894,911.11 |
| 持续经营净利润 | 162,838,922.82 | 103,373,861.49 | 29,864,395.86 | 123,894,911.11 |
| 归属于母公司股东的净利润 | 148,633,516.03 | 92,889,034.14 | 25,668,714.68 | 101,490,338.51 |
| 少数股东损益 | 14,205,406.79 | 10,484,827.35 | 4,195,681.18 | 22,404,572.6 |
| (一)基本每股收益 | 0.95 | 0.59 | 0.16 | 0.65 |
| (二)稀释每股收益 | 0.95 | 0.59 | 0.16 | 0.65 |
| 八、其他综合收益 | 45,727,160.69 | 95,327,620.61 | 81,339,307.08 | -24,691,987.33 |
| 归属于母公司股东的其他综合收益 | 45,727,160.69 | 95,327,620.61 | 81,339,307.08 | -24,691,987.33 |
| 九、综合收益总额 | 208,566,083.51 | 198,701,482.1 | 111,203,702.94 | 99,202,923.78 |
| 归属于母公司股东的综合收益总额 | 194,360,676.72 | 188,216,654.75 | 107,008,021.76 | 76,798,351.18 |
| 归属于少数股东的综合收益总额 | 14,205,406.79 | 10,484,827.35 | 4,195,681.18 | 22,404,572.6 |
| 公告日期 | 2023-10-28 | 2023-08-01 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |